“AFP” quoted the official in US Food and Drug AdministrationStephen Hahn, as saying that “Allow these treatments With antibodies Monoclonal therapy may allow patients to avoid hospitalization and reduce the burden on our healthcare system. ”
For his part, CEO of Regeneron, Leonard Schleifer, said that this constitutes “an important step in the fight against Covid-19, as patients at high risk in the United States will be able to obtain a promising treatment early in the course of infection.”
The green light was given to treat Regeneron, called Regen-Cove-2, which is a combination of two antibodies, after it was shown to reduce Covid-19 cases that require hospitalization or emergency rooms.
The American company “Pfizer” and its German partner “BountechOn Friday, they announced that they had submitted a request to the US Food and Drug Administration to approve the emergency use of the Covid-19 vaccine.
The companies expect the Food and Drug Administration to grant approval for emergency use by mid-December.
And they said that they would start charging the doses immediately, knowing that “Pfizer“I expected to have 50 million vaccine doses ready this year, enough to protect 25 million people.